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Abstract
Background: Cystic fibrosis is the most common fatal autosomal recessive genetic disease in the
Caucasian population. Osteoporosis is increasingly being recognised as an important complication
in people with cystic fibrosis.
Methods: A descriptive study of adult cystic fibrosis patients receiving care at a Canadian tertiary
care hospital was conducted to evaluate the prevalence of osteoporosis, the prevalence of non-
vertebral fractures, and the change in bone mineral density during the course of a year. Data on
bone mineral density were obtained for 40 adult cystic fibrosis patients by reviewing dual x-ray
absorptiometry scans taken at baseline (when annual scans became standard clinical practice) and
one year prior to baseline. Data on prevalent fractures were obtained by reviewing all available
patient charts. Clinical and laboratory data were collected from an existing clinic database.
Results: Over half of the 40 patients had reduced T- and Z-scores at baseline. For the 27 patients
who had data available one year prior to baseline, total hip and lumbar spine bone mineral density
had decreased by 3.04% and 0.86% after one year while total body bone mineral density had not
changed significantly. Four prior non-vertebral fractures were reported in three patients (1,146
patient-years).
Conclusion: This study confirms that osteoporosis is a significant problem in adult cystic fibrosis
patients, and constitutes the first published evidence of cystic fibrosis bone disease in Canadians.
Background
Cystic fibrosis (CF) is the most common fatal autosomal
recessive genetic disease in the Caucasian population,
affecting 30,000 Americans and about the same number
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of Europeans [1]. In the past, approximately one third of
individuals with CF lived to the age of 18 and even fewer
lived past the age of 30. Today, the median survival in
Canada is greater than 30 years [2]. Advances in medical
science have increased life expectancy for CF patients and
as a result long-term sequelae of the disease such as oste-
oporosis and liver disease are becoming apparent in late
adolescence and into adulthood.
The etiology of osteoporosis in CF remains unknown,
although factors such as corticosteroid use, vitamin D
malabsorption, hypogonadism, inflammation, malnutri-
tion, and physical inactivity are thought to be involved
[3–5]. There is an increased prevalence of osteopenia and
osteoporosis in CF patients compared with the general
population. Studies have estimated that between 24 to
58% of adult CF patients are osteopenic [6–12].
The purpose of this descriptive study was to evaluate the
prevalence of osteoporosis, the prevalence of non-verte-
bral fractures, and the annual change in bone mineral
density (BMD) in a population of Canadian adult CF
patients.
Methods
All adult CF patients aged 18 or older attending a tertiary
care hospital in Hamilton, Ontario, Canada (n = 46) were
considered for inclusion in this study. CF was diagnosed
symptomatically and genetically.
Bone mineral density (BMD) was measured at the lumbar
spine, femoral neck, and total hip using a Hologic QDR-
4500A dual x-ray absorptiometry (DXA) machine and was
reported as gm / cm2, T-scores (compared to the young
adult peak bone mass for gender-matched controls) and
Z-scores (compared to age- and gender-matched controls)
for the hip, lumbar spine, and total body. According to cri-
teria established by the World Health Organisation, a T-
score of -1.0 to -2.5 indicates osteopenia, while a T-score
below -2.5 indicates osteoporosis [13]. The scanner was
calibrated daily with a spine phantom to ensure all meas-
urements were reliable. Reports were obtained from the
Department of Nuclear Medicine at Hamilton Health Sci-
ences. Data were collected for scans performed in 1999,
and where available for scans performed in 1998.
All available patient charts were reviewed to elicit all prior
clinical, non-vertebral fractures (with or without trauma).
Clinical and laboratory data collected in 1999 was
obtained from a clinic database, and was used to describe
the study population. Dietary calcium intake was assessed
by a dietitian using a combination of a 24-hour recall and
a food frequency questionnaire. Data on the cumulative
use of oral corticosteroids was obtained from the clinic
database, a review of all available patient records, and a
review of records from the in-patient pharmacy located in
the tertiary care hospital.
Paired, two-tailed, one-sample t-tests (alpha = 0.05) and
95% confidence intervals (CI) were used to determine
whether the mean changes in BMD were significantly dif-
ferent from baseline.
Results
Study Population
DXA scans are routinely performed on all patients attend-
ing the adult CF clinic (minimum age 18 years). Of the 46
patients attending the clinic at the time of the study, six
were excluded because they had no DXA scans available,
either because they were new to the clinic (two), attended
clinic irregularly (three) or refused to be tested (one). The
study population therefore consisted of 40 patients (23
women). Three patients had received an organ transplant
at the time of study (two lung, one liver). Most patients
had adequate daily dietary calcium intake as estimated by
a dietitian (less than 500 mg in six patients, 500–800 mg
in three, 800–1200 mg in eleven, and more than 1200 mg
in seventeen). Four patients received daily calcium sup-
plementation (mean [SD] 2188 [1546] mg / day), not
including those receiving the calcium component of etid-
ronate and calcium therapy for osteoporosis. The mean
[SD] serum vitamin D level (taken at various times during
the year) was 24.8 [13.8] ng / mL, with values ranging
from one to 78. All patients received vitamin D supple-
mentation in combination with vitamins A, E, and K
(mean [SD] 666.7 [270.4] IUD / day). Despite supple-
mentation, 19 patients had a vitamin D level below 25 ng
/ mL. Data on past use of an oral contraceptive was avail-
able for 20 of the 23 women in the study. Twenty-one
patients had received oral or intravenous corticosteroids,
with a mean [SD] cumulative dose of 1659 [2793] mg and
a ranging up to 14,685 mg. Fifteen women had used an
oral contraceptive, eight of which were current users. The
mean [SD] duration of use was 5.6 [4.2] years, and ranged
from two weeks to 13 years. Seven patients had received
etidronate and calcium therapy (90 day cyclical treatment
for osteoporosis, 14 days etidronate disodium followed
by 76 days of CaCO3). Two of the 23 women were post-
menopausal, and one had received hormone replacement
therapy (refer to Tables 1,2, and Figure 1).
BMD at Baseline
Over half of the 40 patients had reduced BMD at the hip
and lumbar spine at baseline (Table 3). Sixteen patients
(40%) had T-scores below -1.0 at one or more sites while
another eight patients (20%) had T-scores below -2.5 at
one or more sites. Twenty-three patients (57.5%) had Z-
scores below -1.0.BMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/13
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Annual Changes in BMD
Previous DXA scans were available for 27 of the 40
patients. The change in BMD from the previous year to
baseline demonstrated a decrease at the hip (left hip -
3.01%, 95% CI -4.76 to -1.26; right hip -3.06%, 95% CI -
4.69 to -1.43) and lumbar spine (-0.86%, 95% CI -2.46 to
0.75). Twenty-one of these patients had whole body scans
on both occasions. The annual change in total body BMD
was negligible (0.0%, SD 1.4%).
Sub-Group Analysis
While the sample size was too small for any adequately
powered sub-group analyses, a description of patients
receiving bisphosphonates is presented here. With regard
to bisphosphonate use, seven patients (aged 21–48, two
males) had been prescribed therapy with etidronate. At
baseline, these seven patients were all osteoporotic at the
lumbar spine and hip. One patient had undergone a lung
transplant, one was awaiting lung transplant, and one had
undergone a liver transplant. One of the women had
reached menopause at age 32. All seven had received oral
corticosteroids, ranging from 350–3650 mg / year. Four
patients had a dietary calcium intake greater than 1200
mg per day, and all were receiving vitamin D supplemen-
tation. The mean [SD] duration of therapy was 269 [89.9]
days and ranged from 90–344 days. Over this short period
of time, there was a mean increase in total body BMD
(11.8%, SD 5.6) and a mean decrease at the hip (-3.5%,
SD 3.9) and lumbar spine (mean -1.6%, SD 6.8). These
differences were not statistically significant.
25-hydroxyvitamin D3 Levels at Baseline for 37 Adult CF Patients Figure 1
25-hydroxyvitamin D3 Levels at Baseline for 37 Adult CF Patients
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Fractures
Four prior clinical, non-vertebral fractures had been
reported for three patients (7.5%, two women). This cor-
responds to 0.35 fractures per 100 patient-years over
1,146 patient-years. Clearly, the small number of fractures
means there is considerable uncertainty associated with
this estimate of fracture prevalence. One patient (male)
had fractured a clavicle, although the mechanism of the
fracture was not recorded. A second patient had fractured
the fourth cervical spine and nose in a car accident. The
final individual had an atraumatic hip fracture while hos-
pitalised and awaiting transplant.
Discussion
BMD at Baseline
More than half of adult CF patients in this study had low
BMD compared to BMD reference populations (Z- and T-
scores).
This observation supports previous studies of osteoporo-
sis in people with CF. A longitudinal study of 151 adult CF
patients aged 15 to 52 [6] showed that 34% of patients
had a Z-score of -2 or less at any site. Additional studies of
osteoporosis in CF report a prevalence of osteopenia rang-
ing from 24–58% and a prevalence of osteoporosis rang-
Table 1: Clinical Characteristics at Baseline for 40 Adult CF Patients
Variable Mean [SD] Range n
Age (years) 28.7 [8.4] 19–52 40
Age at first menstruation (years) 12.9 [1.5] 11–16 17
Height (cm) 166.4 [8.4] 150–183 38
Weight (kg) 57.4 [8.0] 43.3–78 38
Body mass index (gm / kg2) 20.6 [2.3] 16.6–25.1 37
VO2max (L / min)1 1.7 [0.6] 0.65–2.65 37
VO2max (% normal) 87.9 [23.4] 37–117 37
FEV1 (L)2 1.9 [0.6] 0.7–3.3 37
FEV1 (% normal) 52.3 [15.7] 22–87 37
DLCO (mL / min / mmHg)3 19.8 [6.5] 2.05–34.2 37
DLCO (% normal) 60.0 [11.6] 40–85 37
Exercise capacity (kpm)4 797.3 [237.4] 400–1300 37
Exercise capacity (% normal) 76.6 [20.4] 41–113 37
Genotype - -
homozygous ∆ F508 12
heterozygous ∆ F508 18
other heterozygous 5
unknown 5
1 VO2max = oxygen consumption during controlled exercise; 2 FEV1 = forced expiratory volume in one second; 3 DLCO = diffusion of lung (carbon 
monoxide); 4 exercise capacity = a measure of power output; measured using Stage 1 Jones protocol
Table 2: Laboratory Values at Baseline for 40 Adult CF Patients
Variable Mean [SD] Range n # of Patients Below 
Normal Range
# of Patients Above 
Normal Range
25-hydroxyvitamin D3 (ng / mL); normal range 
16–74 ng / mL *
24.8 [13.8] 1–78 37 8 1
Calcium (mmol / L); normal range 2.20–2.58 
mmol / L
2.3 [0.1] 2.01–2.56 36 1 0
Phosphate (mmol / L); normal range 0.80–1.45 
mmol / L
1.2 [0.2] 0.72–1.58 37 0 4
Parathyroid hormone (pg / mL); normal range 
10–65 pg / mL
54.6 [80.0] 14–360 17 0 2
Total alkaline phosphatase (IU / L); normal 
range 50–120 IU / L
120.7 [78.3] 49–490 37 1 11
Gamma-glutamyl aminotransferase (IU / L); 
normal < 45 IU / L
34.7 [39.5] 6–140 36 0 9
* taken at various times during the yearBMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/13
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ing from 4–76% [7–12]. Heterogeneity in age,
corticosteroid use, organ transplantation, and other risk
factors may account for this large variation. The preva-
lence of low BMD in CF patients may represent decreased
bone building, increased bone resorption [3], or both
[14].
Annual Changes in BMD
This paper provides important information on longitudi-
nal changes in BMD. Patients with a DXA scan one year
prior to baseline assessment showed a mean decrease in
BMD at the hip and lumbar spine, while total body BMD
remained stable. These 27 patients represent a skewed
sample since they underwent dual x-ray absorptiometry
scans because of active referral rather than standard clini-
cal practice. The majority of these patients had received or
were receiving treatment with etidronate or oral corticos-
teroids, therefore these data do not represent the natural
progression of bone loss in people with cystic fibrosis. It
is interesting to note that CF patients were more likely to
lose BMD at the hip than at the spine, possibly due to cal-
cium and vitamin D deficiency [15]. The decrease in bone
mass may have been caused by the use of oral corticoster-
oids [16]. There is a need to determine whether these
changes are clinically significant. A review of patient
charts revealed no significant changes in height. This was
not surprising since the study population consisted of
adults who were not actively fracturing. There were some
fluctuations in weight over the one year prior to baseline.
A limited sub-group analysis of etidronate plus calcium
used by five patients for between 90 and 344 days showed
a non-significant increase in total body BMD and a non-
significant decrease in BMD at the hip and lumbar spine.
Given the small sample size of this sub-group, the varia-
tion in response, and the variation in duration of therapy
it is difficult to determine the clinical effect of etidronate
plus calcium on osteoporosis in patients with cystic
fibrosis.
Three published studies have examined the annual pro-
gression of osteoporosis in CF patients. Bhudhikanok and
colleagues [17] examined 21 adult CF patients (15
females) with a mean age of 27 years and found no statis-
tically significant annual changes at the lumbar spine,
femoral neck, and total body. A study of 153 adult CF
patients (70 females) aged 15–52 [6] found an annual
increase (standard deviation) of 0.9% (4.0%, p = 0.032)
at the distal forearm and 0.1% (4.6%, p = ns) at the
ultradistal forearm as measured by single x-ray absorpti-
ometry. This same study found an annual decrease of
0.4% (4.3%, p = ns) at the lumbar spine and 1.8% (3.6%,
p < 0.001) at the total hip as measured by DXA. The
authors published a subsequent report of 114 adult
patients [18]. In patients aged 24 years or younger (n =
55), there was a mean annual increase of 2.9% (95% CI
1.6% to 4.2%) at the distal forearm, but a mean annual
decrease of 2.5% (95% CI -3.8% to -1.2%) at the femoral
neck and a decrease of 2.2% (95% CI -3.3% to -1.0%) for
the total hip (p < 0.001 for all analyses). In patients aged
25 years or older (n = 59), there was a mean annual
decrease of 0.8% (95% CI -1.5 to -0.1%, p = 0.026) at the
distal forearm, a decrease of 1.9% (95% CI -2.9% to -
0.8%, p < 0.001) at the femoral neck, and a decrease of
1.5% (95% CI -2.4% to -0.6%, p = 0.001) for the total hip.
Fractures
Three patients had four prior non-vertebral fractures. This
represents a smaller fracture rate than reported in the
literature, although this study is limited by a small sample
size and a small number of patient-years of follow-up.
Note that this study only examined the incidence of clini-
cal non-vertebral fractures.
Aris et al [7] studied fractures in 70 adult CF patients
referred for lung transplantation, a population with a
higher risk of fractures than the patients in this study. The
rate of clinical, non-vertebral fractures in men aged 25–45
years was 8.5 per 100 patient-years compared to a popu-
lation rate of 2.8 (p < 0.05). The rate was slightly lower in
women aged 16–34 years: 3.7 fractures per 100 patient-
years compared to 1.7 in the general population (p <
0.05). Vertebral compression and rib fractures were 100-
and 10-fold more common than predicted (p < 0.001),
respectively. Haworth et al [6] found a history of fracture
in 51 of the 151 patients aged 15–52. Since a greater sam-
ple size is required to generate meaningful data, no con-
Table 3: Mean BMD at Baseline for 40 Adult CF Patients
gm / cm2 t-score z-score
mean [SD] range n mean [SD] range n mean [SD] range n
total body 1.2 [0.1] 0.93 to 1.44 37 - - - - - -
left hip 0.9 [0.2] 0.61 to 1.21 40 -1.0 [1.1] -3.45 to 1.55 40 -0.9 [1.1] -3.32 to 1.01 36
right hip 0.9 [0.1] 0.62 to 1.12 39 -1.0 [1.1] -3.45 to 1.25 40 -1.0 [1.1] -3.31 to 1.28 36
lumbar spine 0.8 [0.1] 0.67 to 1.13 39 -1.2 [1.2] -3.46 to 1.87 40 -1.1 [1.3] -3.30 to 2.72 40BMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/13
Page 6 of 7
(page number not for citation purposes)
clusions about the prevalence of fractures in CF patients
can be drawn from this study.
Laboratory Values
Despite vitamin D3 supplementation in the form of a fat-
soluble multivitamin, there was a high prevalence of vita-
min D deficiency (refer to Table 2 and Figure 1). Nineteen
patients had serum vitamin D levels below 25 ng / mL, the
lower limit of normal. Deficiency is not unexpected given
the latitude of the treatment centre, and given that vita-
min D levels were measured at various times during the
year and are therefore sensitive to seasonal variation [19].
One patient had elevated total alkaline phosphatase (AP)
and parathyroid hormone (PTH) levels and was vitamin
D deficient, indicating possible osteomalacia or hyperpar-
athyroidism rather than osteoporosis. An additional five
patients had elevated total AP and gamma-glutamyl ami-
notransferase (GGT) levels, which indicates possible liver
disease. Note that GGT levels are normally a measure of
liver function and usually not associated with osteoporo-
sis. Six patients had elevated total AP levels with normal
PTH and GGT levels, a profile that could represent either
osteoporosis or biliary obstruction.
Study Limitations
This study is limited by a relatively small sample size, but
is a pilot for a larger study to be conducted in the future.
Patients with established osteoporosis were more likely to
have had at least two DXA scans, therefore data on annual
changes in BMD may reflect changes in patients with
more severe bone disease. Data on clinical, non-vertebral
fractures relied on all available patient charts, while data
on vertebral fractures were unavailable. Information on
hormonal levels was not available. Data were not strati-
fied by patient characteristics such as etidronate use, corti-
costeroid use, or gender. Regression will be conducted in
subsequent studies with larger sample size.
Conclusions
This study confirms that osteoporosis is a significant prob-
lem in adult CF patients. Since all previous studies were
conducted in the USA or the UK, this study provides data
from a Canadian context. Additional studies are war-
ranted to further describe annual changes in BMD and to
determine what magnitudes of change in BMD are clini-
cally relevant.
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